SCHEMBL5858640

SCHEMBL5858640

FC(F)(F)c1ccc2c(c1)nnn2C1CCN(CCC(c2ccccc2)c2ccccc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.61
LMNA P02545 6/20 0.61
NPSR1 Q6W5P4 6/20 0.61
SMN1; SMN2 Q16637 4/20 0.61
MAPT P10636 4/20 0.61
HTT P42858 4/20 0.61
USP2 O75604 3/20 0.61
POLB P06746 1/20 0.61
HPGD P15428 1/20 0.54
PKM P14618 1/20 0.53
MAPK1 P28482 3/20 0.53
GAA P10253 2/20 0.52
GALK1 P51570 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.49
TSHR P16473 1/20 0.49
CCR5 P51681 2/20 0.47
CYP2D6 P10635 1/20 0.47
OPRM1 P35372 1/20 0.46
OPRD1 P41143 1/20 0.46
OPRL1 P41146 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5857440 0.84 CYP2D6 (0.61) ALDH1A1LMNANPSR1USP2GAA
SCHEMBL25802934 0.79 PKM (0.64) ALDH1A1LMNANPSR1SMN1; SMN2MAPT
SCHEMBL27917816 0.75 LMNA (0.72) ALDH1A1LMNANPSR1SMN1; SMN2MAPT
SCHEMBL5857451 0.74 CYP2D6 (0.52) ALDH1A1USP2GAACCR5CYP2D6
SCHEMBL904850 0.73 USP2 (0.60) ALDH1A1LMNANPSR1SMN1; SMN2MAPT
SCHEMBL2544136 0.73 LMNA (0.56) ALDH1A1LMNANPSR1SMN1; SMN2MAPT
Hydrochloric Acid SCHEMBL5857416 0.72 LMNA (0.55) ALDH1A1LMNANPSR1SMN1; SMN2MAPT
SCHEMBL14834301 0.69 PKM (0.66) ALDH1A1LMNANPSR1SMN1; SMN2MAPT
SCHEMBL13929350 0.67 SIGMAR1 (0.71) CCR5
SCHEMBL13929341 0.67 SIGMAR1 (0.74) HTTPOLBCCR5OPRM1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6989393-B2 Ccr5 modulators benzimidazoles or benzotriazoles ASTRAZENECA AB (SE) 2006-01-24 US disclosed
US-20030119869-A1 Ccr5 modulators benzimidazoles or benzotriazoles ASTRAZENECA AB (SE) 2003-06-26 US disclosed
EP-1265870-A1 NEW CCR5 MODULATORS: BENZIMIDAZOLES OR BENZOTRIAZOLES AstraZeneca AB (SE) 2002-12-18 EP disclosed
WO-2001066525-A1 NEW CCR5 MODULATORS: BENZIMIDAZOLES OR BENZOTRIAZOLES ASTRAZENECA AB (SE) 2001-09-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119869-A1 Ccr5 modulators benzimidazoles or benzotriazoles CCR5, CCR2, CXCR4 ALDH1A1 1599/4885LMNA 4192/4885NPSR1 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.